Wei Xu

Wei Xu
Partner

Mr. Wei Xu is a Partner at Decheng Capital and has been with the firm since 2017. He is currently serving on the boards of Accuragen, AnHeart Therapeutics, Centricity Vision, Ketai Medical, MDCO and Mynosys.

At Decheng, Mr. Xu focuses on investments in biotechnology and medical device companies in China and US. Prior to joining Decheng, Mr. Xu was Managing Director of Denlux Capital and served on the boards of Cirina (acquired by GRAIL), BEST (NYSE: BSTI), and SINOMED (688108.CH). His investment portfolio also includes Shengda (002259.SZ), SCYAHUA (002497.SZ), Dadifengyuan (acquired by Yonker, 300187.SZ), SZJECH (acquired by Orient Scape, 002310.SZ), NCM China (acquired by Tencent), Hsyuntai, Baoji Clinic, Immune-Onc., etc.

Mr. Xu received Master degree in Economics from University of Oslo, and a BS degree in College of Biomedical Engineering & Instrument Science from Zhejiang University.

 

Min Cui, Ph.D.
Managing Director
Victor E. Tong, Jr.
Partner
Nick Pliam, M.D., Ph.D.
Partner
Y. Katherine Xu, Ph.D.
Partner
Qiang Xu, Ph.D.
Partner
Wei Xu
Partner
Peter Colabuono
Principal
Tony Tong, Ph.D.
Principal
Aaron Li, MBA
Vice President
Yang Lu, MBA
Vice President
Dan Zabrowski, Ph.D.
Venture Partner
 
Copyright ? 2011 Decheng Capital LLC. All Rights Reserved.
poronovideos少妇_藏经阁福利导福航_青青国产揄拍视频